In summary, we have uncovered a novel mechanism by which CRNDE mediates tumor growth and sorafenib resistance via interactions with p300 that may offer effective treatment avenues to combat sorafenib resistance in HCC. The gene discussed is EP300; the disease is hepatocellular carcinoma.